Beobachtungsstudie
Quality of life for androgen receptor targeted agents in patients with metastatic castration resistant prostate cancer
Bratislava Medical Journal · 2024
DOI: 10.4149/bll_2024_89 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Bratislava Medical Journal, 2024. Verfasst von Monika Kuzma und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Quality of Life, Prostatic Neoplasms, Castration-Resistant, Benzamides, Phenylthiohydantoin.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Quality of LifeProstatic Neoplasms, Castration-ResistantBenzamidesPhenylthiohydantoinNitrilesHumansMaleAgedProspective StudiesMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsAndrostenesPrednisoneAged, 80 and overAbiraterone AcetateReceptors, Androgen
Substanzen
BenzamidesenzalutamidePhenylthiohydantoinNitrilesAndrostenesPrednisoneabirateroneAbiraterone AcetateReceptors, Androgen
Zitieren
APA
Kuzma, M., Nekvindova, L., & Kliment, J. (2024). Quality of life for androgen receptor targeted agents in patients with metastatic castration resistant prostate cancer. Bratislava Medical Journal. https://doi.org/10.4149/bll_2024_89
Vancouver
Kuzma M, Nekvindova L, Kliment J. Quality of life for androgen receptor targeted agents in patients with metastatic castration resistant prostate cancer. Bratislava Medical Journal. 2024. doi:10.4149/bll_2024_89
BibTeX
@article{Kuzma2024,
author = {Kuzma, Monika and Nekvindova, Lucie and Kliment, Jan},
title = {Quality of life for androgen receptor targeted agents in patients with metastatic castration resistant prostate cancer},
journal = {Bratislava Medical Journal},
year = {2024},
doi = {10.4149/bll_2024_89}
}
EUVIMED